You are here
- Home
- Therapy Areas
- Neuroscience
A Phase I, Randomised, Open-label, 3 way Cross-over Study in Healthy Volunteers to Demonstrate the Bioequivalence of the Naloxegol 25 mg Commercial and Phase III Formulations and to Assess the Effect of Food Administration on the Pharmacokinetics of the Commercial Formulation.
- Disease
- bioequivalence
- Drug Name
- AstraZeneca Neuroscience Development Drugs
- Generic Name
- Naloxegol
- Sponsor
- AstraZeneca
- Drug Status
- In Development
- Phase
- I
- Start Date
- Jan 18, 1971
- Study Name
- D3820C00018
- Study Id
- D3820C00018
- ClinicalTrials.gov ID
- NCT01623609
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
